185 related articles for article (PubMed ID: 18513434)
41. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
42. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.
Ooki A; Maleki Z; Tsay JJ; Goparaju C; Brait M; Turaga N; Nam HS; Rom WN; Pass HI; Sidransky D; Guerrero-Preston R; Hoque MO
Clin Cancer Res; 2017 Nov; 23(22):7141-7152. PubMed ID: 28855354
[No Abstract] [Full Text] [Related]
43. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
[TBL] [Abstract][Full Text] [Related]
44. Accurate molecular detection of non-small cell lung cancer metastases in mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration.
Wallace MB; Block MI; Gillanders W; Ravenel J; Hoffman BJ; Reed CE; Fraig M; Cole D; Mitas M
Chest; 2005 Feb; 127(2):430-7. PubMed ID: 15705978
[TBL] [Abstract][Full Text] [Related]
45. Transcriptomic Analysis in Liquid Biopsy Identifies Circulating PCTAIRE-1 mRNA as a Biomarker in NSCLC.
Chang JW; Shih CL; Wang CL; Luo JD; Wang CW; Hsieh JJ; Yu CJ; Chiou CC
Cancer Genomics Proteomics; 2020; 17(1):91-100. PubMed ID: 31882554
[TBL] [Abstract][Full Text] [Related]
46. Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer.
Chong IW; Chang MY; Chang HC; Yu YP; Sheu CC; Tsai JR; Hung JY; Chou SH; Tsai MS; Hwang JJ; Lin SR
Oncol Rep; 2006 Nov; 16(5):981-8. PubMed ID: 17016581
[TBL] [Abstract][Full Text] [Related]
47. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
[TBL] [Abstract][Full Text] [Related]
48. Identification and diagnostic value of pleural fluid periostin and serum periostin of malignant pleural effusions in patients with non-small-cell lung cancer.
Wang J; Fu J; Shen Q; Zhang F; Wang Y; Wu LL
J Clin Lab Anal; 2019 Sep; 33(7):e22943. PubMed ID: 31268191
[TBL] [Abstract][Full Text] [Related]
49. Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma.
Yu H; Huang X; Zhu Z; Hu Y; Ou W; Zhang L; Zhou N
Chin J Cancer Res; 2014 Feb; 26(1):89-94. PubMed ID: 24653630
[TBL] [Abstract][Full Text] [Related]
50. Detection of micrometastases in peripheral blood of non-small cell lung cancer with a refined immunomagnetic nanoparticle enrichment assay.
Li Q; Qi H; Zhou HX; Deng CY; Zhu H; Li JF; Wang XL; Li FR
Int J Nanomedicine; 2011; 6():2175-81. PubMed ID: 22114481
[TBL] [Abstract][Full Text] [Related]
51. Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.
Thompson JC; Fan R; Black T; Yu GH; Savitch SL; Chien A; Yee SS; Sen M; Hwang WT; Katz SI; Feldman M; Vachani A; Carpenter EL
Lung Cancer; 2019 Jan; 127():25-33. PubMed ID: 30642547
[TBL] [Abstract][Full Text] [Related]
52. Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].
Coelho AL; Araújo A; Gomes M; Catarino R; Marques A; Medeiros R
PLoS One; 2014; 9(2):e90009. PubMed ID: 24587185
[TBL] [Abstract][Full Text] [Related]
53. Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases.
Benlloch S; Galbis-Caravajal JM; Alenda C; Peiró FM; Sanchez-Ronco M; Rodríguez-Paniagua JM; Baschwitz B; Rojas E; Massutí B
Ann Oncol; 2009 Jan; 20(1):91-7. PubMed ID: 18664559
[TBL] [Abstract][Full Text] [Related]
54. Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer.
Sun L; Chen Y; Su Q; Tang X; Liang Y; Che G; Luo F
Med Sci Monit; 2016 Feb; 22():647-55. PubMed ID: 26918265
[TBL] [Abstract][Full Text] [Related]
55. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
[TBL] [Abstract][Full Text] [Related]
56. MiRNA-30 Play an Important Role in Non-Small Cell Lung Cancer (NSCLC).
Sui JYAX
Clin Lab; 2020 Apr; 66(4):. PubMed ID: 32255283
[TBL] [Abstract][Full Text] [Related]
57. Plasma LUNX mRNA, a non-invasive specific biomarker for diagnosis and prognostic prediction of non-small cell lung cancer.
Zhou HX; Yang MX; Wang Y; Cao WM; Lu KF; Zong LY; Wu RQ; Zhang P
Am J Cancer Res; 2016; 6(2):452-8. PubMed ID: 27186415
[TBL] [Abstract][Full Text] [Related]
58. Expression and significance of Pin1 mRNA in circulating mononuclear cells from non-small cell lung cancer patients during perioperative period.
Ai ZH; Zhang WX; Luo WJ; Huang LJ; Pan Y
Ai Zheng; 2009 Mar; 28(3):268-73. PubMed ID: 19619441
[TBL] [Abstract][Full Text] [Related]
59. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer.
Xie Y; Zhang Y; Du L; Jiang X; Yan S; Duan W; Li J; Zhan Y; Wang L; Zhang S; Li S; Wang L; Xu S; Wang C
Mol Oncol; 2018 May; 12(5):648-658. PubMed ID: 29504701
[TBL] [Abstract][Full Text] [Related]
60. [Role of heterogeneous nuclear ribonucleoprotein A2/B1 protein in the pathogenesis of non-small cell lung cancer].
Shi Y; Chen Y; Hou YY; Ji CH; Hu Q; Zhou Y; Su JA; Tan YS
Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):110-4. PubMed ID: 21575478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
